ASX Health Stocks: UK FSA welcomes Cann’s CBD capsules onto its approved list
Health & Biotech
Health & Biotech
Link copied to
Cannabis company Cann Group (ASX:CAN) has received the green light from the UK FSA for its CBD capsules.
Cann says the CBD capsules made by its European subsidiary, Satipharm, have been added to the list of approved CBD products permitted to be sold in the UK.
Satipharm has been supplying the capsules in the UK market since 2016. But in 2019, new regulations were enacted in the UK requiring all suppliers of CBD food supplements to submit applications for Novel Food Authorisation.
The list released today by the UK FSA marks a milestone for the UK CBD industry, and removes any uncertainty within the supply chain around CBD products.
Over 800 product dossiers were submitted by various CBD manufacturers to the UK FSA for review. Of these, the FSA has rejected over 600 dossiers which did not satisfy the validation criteria.
“The inclusion of the Satipharm products in the list demonstrates Cann’s real commitment to quality and consumer safety,” commented Cann CEO, Peter Crock.
“We see this as a great opportunity to accelerate our sales of the Satipharm range in the UK, and we look forward to keeping our shareholders updated as our distribution and sales grow in the coming months.”
Satipharm has patented Advanced CBD capsules that are clinically proven to deliver approximately 3.5 times higher total bioavailability (proportion of the substance entering and affecting the body).
Still in the UK, Starpharma (ASX:SPL) says it will relaunch its nasal anti-viral spray VIRALEZE in the kingdom.
The company says it has successfully resolved the queries raised last year by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
In June 2021, sales and promotion of VIRALEZE in the UK were temporarily paused while Starpharma addressed concerns from the MHRA.
In preparation for relaunch, Starpharma is currently in discussions with retail partner LloydsPharmacy regarding logistics.
INOVIQ(ASX:IIQ) and The University of Queensland (UQ) have expanded their collaboration to develop a world-first exosome-based ovarian cancer screening test.
Exosomes are a type of extracellular vesicle (EV) that are released by most cells into biofluids such as blood, urine and saliva.
They contain important information about their parent cell that can be used for the identification of biomarkers, diagnosis and treatment of disease.
INOVIQ has the exclusive option to license the rights to the commercialisation of the final testing product.
Cannabis company Creso Pharma (ASX:CPH) has signed a non-binding Letter of Intent (LOI) with Laboratorios Brouwer to broaden its LATAM markets footprint.
The deal will see Brouwer and its Latin American representative Medara market Creso’s range of anibidiol products.
Initial target countries include Argentina, Chile, Perú, Brazil, Colombia and Mexico.
Imricor (ASX:IMR) signed a pricing agreement with Policlinico Casilino, making it the 15th Imricor site in Europe and the first in Italy.
The agreement sets pricing for Imricor’s cardiac ablation products, and has an initial term of one year.
Imricor says the deal is critical in growing the number of sites performing realtime iCMR cardiac ablation procedures in Europe.
Planning is now underway for procedures to commence in the second quarter of 2022.
At Stockhead we tell it like it is. While Creso Pharma is a Stockhead advertiser, it did not sponsor this article.